stock offering

Biocept closed a $14.8 million public offering earlier this year and recently reported ending the second quarter with $2.6 million in cash and cash equivalents.

The firm will sell more than 14 million shares of its common stock for $4.25 per share.

The firm did not disclose how many shares it planned to sell or how much money it expects to raise.

The filing follows the firm's recent close of a $2 million non-convertible debt instrument and CE marking for its tuberculosis test.

Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.

The company had previously said that it expected gross proceeds of up to $22.6 million if rights to all 25,000 securities units were exercised.

Proceeds from the offering could be used to fund acquisitions, to repay existing debts, or for working capital.

The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.

The firm has reached a deal with certain investors for the purchase of units comprising OncoCyte common shares and warrants to purchase shares.

Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.

Pages

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.